The FDA's Arthritis Advisory Committee is scheduled on July 29 to review Roche Holding's Actemra for approval. The company believes that the drug, which has been approved in Japan, will gain competitive advantage as an alternative to anti-tumor necrosis factor drugs used in rheumatoid arthritis.

Full Story:

Related Summaries